Curis Provides Third Quarter 2026 Business Update Curis Provides Third Quarter 2026 Business Update Curis, Inc. Nov 12, 2026, 16:01 ET Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, ...